{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T05:25:24Z","timestamp":1793424324535,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journalofinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jinf.2024.106376","type":"journal-article","created":{"date-parts":[[2024,12,15]],"date-time":"2024-12-15T03:28:56Z","timestamp":1734233336000},"page":"106376","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8332-6166","authenticated-orcid":false,"given":"Sarah","family":"Soueges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2618-2706","authenticated-orcid":false,"given":"Emmanuel","family":"Faure","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perrine","family":"Parize","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Lanternier-Dessap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herv\u00e9","family":"Lecuyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Martin-Blondel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Gaborit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Blot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Magallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6345-9685","authenticated-orcid":false,"given":"Xavier","family":"Brousse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marin","family":"Lahouati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9437-1977","authenticated-orcid":false,"given":"Anne-Sophie","family":"Brunel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloise","family":"Le Banner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Camelena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-0901","authenticated-orcid":false,"given":"Romaric","family":"Larcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alix","family":"Pantel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Melica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyvan","family":"Razazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Danion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oana","family":"Dumitrescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-4763","authenticated-orcid":false,"given":"Baptiste","family":"Hoellinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Ader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.jinf.2024.106376_bib1","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1001\/jama.2016.16477","article-title":"Prevalence of immunosuppression among US adults, 2013","volume":"316","author":"Harpaz","year":"2016","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jinf.2024.106376_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/15748847113089990062","article-title":"Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge?","volume":"9","author":"Curcio","year":"2014","journal-title":"Curr Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jinf.2024.106376_bib3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.idc.2016.02.008","article-title":"Antibiotic-resistant infections and treatment challenges in the immunocompromised host","volume":"30","author":"Dumford","year":"2016","journal-title":"Infect Dis Clin North Am"},{"issue":"2","key":"10.1016\/j.jinf.2024.106376_bib4","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.jinf.2024.106376_bib5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jinf.2024.106376_bib6","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant Gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.jinf.2024.106376_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"11","key":"10.1016\/j.jinf.2024.106376_bib8","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1093\/jac\/dkad298","article-title":"Cefiderocol use for the treatment of infections by carbapenem-resistant Gram-negative bacteria: an Italian multicentre real-life experience","volume":"78","author":"Piccica","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.jinf.2024.106376_bib9","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02142-21","article-title":"Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii","volume":"66","author":"Falcone","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2024.106376_bib10","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/antibiotics10060652","article-title":"Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d Gram-negative severe infections: real-life case series and future perspectives","volume":"10","author":"Bavaro","year":"2021","journal-title":"Antibiotics"},{"issue":"1","key":"10.1016\/j.jinf.2024.106376_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106830","article-title":"Clinical efficacy and safety of novel antibiotics for complicated urinary tract infection: a systematic review and meta-analysis of randomized controlled trials","volume":"62","author":"Hung","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.jinf.2024.106376_bib12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13613-023-01146-5","article-title":"Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence","volume":"13","author":"Viale","year":"2023","journal-title":"Ann Intensive Care"},{"issue":"3","key":"10.1016\/j.jinf.2024.106376_bib13","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmi.2022.11.005","article-title":"Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series","volume":"29","author":"Hoellinger","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.jinf.2024.106376_bib14","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.jinf.2024.106376_bib15","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1097\/INF.0000000000004347","article-title":"Use of cefiderocol in the management of children with infection or colonization with multi-drug resistant Gram-negative bacteria","volume":"43","author":"Schmid","year":"2024","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.jinf.2024.106376_bib16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.3390\/antibiotics12040746","article-title":"Cefiderocol efficacy in a real-life setting: single-centre retrospective study","volume":"12","author":"Palermo","year":"2023","journal-title":"Antibiotics"},{"issue":"11","key":"10.1016\/j.jinf.2024.106376_bib17","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1093\/cid\/cix646","article-title":"Antimicrobial resistance in gram-negative rods causing bacteremia in hematopoietic stem cell transplant recipients: intercontinental prospective study of the infectious diseases working party of the European Bone Marrow Transplantation Group","volume":"65","author":"Averbuch","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jinf.2024.106376_bib18","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1093\/cid\/ciz319","article-title":"Inappropriate empirical antibiotic treatment in high-risk neutropenic patients with bacteremia in the era of multidrug resistance","volume":"70","author":"Martinez-Nadal","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.jinf.2024.106376_bib19","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00618-22","article-title":"Efficacy of cefiderocol in experimental Stenotrophomonas maltophilia pneumonia in persistently neutropenic rabbits","volume":"66","author":"Petraitis","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.jinf.2024.106376_bib20","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and in vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"},{"issue":"6","key":"10.1016\/j.jinf.2024.106376_bib21","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1016\/S1470-2045(20)30725-7","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the use of antibiotics in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Lehrnbecher","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jinf.2024.106376_bib22","doi-asserted-by":"crossref","first-page":"1156.e1","DOI":"10.1016\/j.cmi.2022.04.013","article-title":"Comparison of disk diffusion, MIC test strip and broth microdilution methods for cefiderocol susceptibility testing on carbapenem-resistant enterobacterales","volume":"28","author":"Bonnin","year":"2022","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324003116?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163445324003116?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T13:51:59Z","timestamp":1740059519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163445324003116"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["S0163445324003116"],"URL":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106376","relation":{},"ISSN":["0163-4453"],"issn-type":[{"value":"0163-4453","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant Gram-negative bacteria: CEFI-ID","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jinf.2024.106376","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.","name":"copyright","label":"Copyright"}],"article-number":"106376"}}